GlassScriptPhysician profile
Todd A Miller
NPI 1558479675
$6,025.42
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,924 · 2020: $871 · 2021: $1,930 · 2022: $1,255 · 2023: $45.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $812.59 | 2019-2022 | |
| Amgen INC. | $669.45 | 2019-2022 | |
| Abbvie INC. | $629.32 | 2019-2022 | |
| Pfizer INC. | $588.76 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.25 | 2019-2022 | |
| Novo Nordisk INC | $311.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $306.18 | 2019-2022 | |
| Amarin Pharma, INC. | $235.85 | 2019-2022 | |
| Astellas Pharma US INC | $185.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $183.26 | 2019-2021 | |
| Esperion Therapeutics, INC. | $159.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $148.29 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $134.08 | 2021 | |
| Allergan, INC. | $128.38 | 2019-2021 | |
| Eisai INC. | $124.08 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $93.13 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $91.82 | 2019-2021 | |
| Daiichi Sankyo INC. | $90.71 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.29 | 2019-2022 | |
| Lilly USA, LLC | $63.92 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.48 | 2021-2022 | |
| Abbott Laboratories | $39.77 | 2021-2022 | |
| Medtronic, INC. | $39.51 | 2021-2022 | |
| Nevro Corp. | $33.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.65 | 2019-2020 | |
| Pacira Therapeutics, INC. | $29.03 | 2020-2021 | |
| Vbi Vaccine (Delaware) INC. | $26.94 | 2023 | Prehevbrio |
| Sanofi-Aventis U.S. LLC | $25.50 | 2019-2021 | |
| Genentech USA, INC. | $23.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.93 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.33 | 2022 | |
| Shire North American Group INC | $14.55 | 2019 | |
| Apria Healthcare LLC | $14.53 | 2021 | |
| Electromed, INC. | $14.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.32 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.03 | 2022 | |
| Glaxosmithkline, LLC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.